Investigating the effects of SGLT2 inhibitors on heart issues from breast cancer treatment
Official title: Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis - SCARA-B
Run by Centre Paul Strauss · NCT06443645 · Data updated 2026-11-12
This study is testing if a diabetes medication can help protect the hearts of women with localized breast cancer who are receiving certain chemotherapy treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Centre Paul Strauss Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | February 17, 2025 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | February 4, 2026 |
| Trial ID | NCT06443645 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 diagnosed with localized breast cancer who are scheduled for first-line surgery or anthracycline-based chemotherapy.
✕Probably not a fit
Patients with a history of heart disease, those currently on anti-SGLT2 medications, or those with significantly impaired kidney or liver function may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients with localized breast cancer who are indicated for anthracycline-based chemotherapy. It aims to understand the role of Sodium-glucose Linked Transporter 2 (SGLT2) inhibitors in mitigating cardiac toxicities associated with anthracycline treatment. The study will assess the frequency and severity of anthracycline-related cardiac toxicities, including heart failure and other cardiovascular complications, in this patient population. By analyzing these effects, the study seeks to provide insights into potential protective strategies against cardiotoxicity during breast cancer treatment.
Why it matters
Potential benefit: If successful, this study could lead to improved cardiac health and overall survival for breast cancer patients undergoing anthracycline chemotherapy.
How similar studies have gone: While various approaches have been explored to address anthracycline-related cardiac toxicities, the specific role of SGLT2 inhibitors in this context is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient \> 18 years old * Diagnosed with localized breast cancer * Indication for first-line surgery or anthracycline-based chemotherapy. Exclusion Criteria: * History of chemotherapy or targeted therapy or immunotherapy administered before inclusion * Patient currently being treated with anti-SGLT2, conversion enzyme inhibitor or ARA2 * Patient with known heart disease (ischemic, rhythmic, valvular, etc.) * Patient with a Glomerular filtration rate \< 45 mL/min/1.73m² according to the pre-therapeutic assessment * Patient with impaired liver function * Patient who is pregnant or breastfeeding * Patient with a second cancer undergoing treatment * Patient under guardianship or curatorship, protection of justice or deprived of liberty
Where it's running
-
Centre Paul Strauss
Strasbourg, France Recruiting
Study contacts
- Principal investigator: Hervé BISCHOFF — Centre Paul Strauss
- Study coordinator: Anne ANTHONY
- Email: promotion-rc@institut-strauss.fr
- Phone: +33(0)388252413
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improved Facial Skin Quality After VYC-12L for Breast Cancer Survivors
This study tests whether intradermal injections of VYC-12L can improve facial skin quality and quality of life in adults who have completed breast cancer treatment.
-
Breast cancer subtypes and outcomes in Colombian women
This study looks back at medical records of women with breast cancer to see how different molecular subtypes relate to survival and recurrence in a single Colombian hospital.
-
Multimodal psychosomatic symptom care for breast cancer: personalized acupuncture care guided by shared decision-making
This study tests whether personalized acupuncture options (manual acupuncture, ear acupuncture, or both) can help women with breast cancer who have anxiety, sleep problems, or fatigue, compared to routine nursing care.
-
Slow Jogging for Breast Cancer Survivors
This study tests whether a 12-week slow jogging program helps sleep quality in women who have completed breast cancer treatment.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Benchmarking AI language models against tumor boards for oncology treatment decisions
This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.